RE: Money management14 May 2020 21:57
If this drug shows efficacy, there is no way it will be £1.50, not a chance. The deal they had before was £230million + royalties. So £230m / 150 m shares = £1.53 a share. But that doesn’t include royalties, and in any case it’s a totally different proposition now as before it was years away from even starting a phase 2 trial, oh, and there was no COVID. Not ramping, these are the facts. It’s just the stumbling block of ‘IF’.